血栓形成和自身免疫性疾病中的膜联蛋白 A2 自身抗体。

Annexin A2 autoantibodies in thrombosis and autoimmune diseases.

机构信息

INSERM ESPRI, ERI29/EA2216 Immunology, Pathology and Immunotherapy, Labex IGO, SFR ScinBios, Réseau canaux ioniques et Réseau épigénétique du Cancéropôle Grand Ouest, European University of Brittany, Brest, France; Center for Autoimmune Diseases Research (CREA) School of Medicine and Health Sciences Universidad del Rosario, Bogotá, Colombia.

INSERM ESPRI, ERI29/EA2216 Immunology, Pathology and Immunotherapy, Labex IGO, SFR ScinBios, Réseau canaux ioniques et Réseau épigénétique du Cancéropôle Grand Ouest, European University of Brittany, Brest, France; Laboratory of Immunology and Immunotherapy, Brest University Medical School Hospital, Morvan, Brest, France; Department of Internal Medicine, Brest University Medical School Hospital, Cavale Blanche, Brest, France.

出版信息

Thromb Res. 2015 Feb;135(2):226-30. doi: 10.1016/j.thromres.2014.11.034. Epub 2014 Dec 13.

DOI:10.1016/j.thromres.2014.11.034

PMID:25533130

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial, venous or small-vessel thrombotic events, and recurrent miscarriages or fetal loss. APS diagnosis is based on the repeated detection of anti-phospholipid (PL) antibodies (Ab), typically associated with anti-β2 glycoprotein I (β2GPI)-Ab. Recent studies suggest that anti-β2GPI Ab activity involves a protein complex including β2GPI and annexin A2 (ANXA2). Anti-ANXA2 Ab recognizes this complex, and these Ab can effectively promote thrombosis by inhibiting plasmin generation, and by activating endothelial cells. Therefore, anti-ANXA2 Ab represent a new biomarker, which can be detected in up to 25% of APS patients. Moreover, anti-ANXA2 Ab have been detected, in thrombotic associated diseases including pre-eclampsia, in other autoimmune diseases, and in cancer.

摘要

抗磷脂综合征（APS）是一种自身免疫性疾病，其特征为动脉、静脉或小血管血栓形成事件，以及复发性流产或胎儿丢失。APS 的诊断基于抗磷脂（PL）抗体（Ab）的重复检测，通常与抗β2 糖蛋白 I（β2GPI）-Ab 相关。最近的研究表明，抗β2GPI Ab 活性涉及包括β2GPI 和膜联蛋白 A2（ANXA2）的蛋白复合物。抗 ANXA2 Ab 识别该复合物，并且这些 Ab 可通过抑制纤溶酶生成和激活内皮细胞来有效促进血栓形成。因此，抗 ANXA2 Ab 代表一种新的生物标志物，可在高达 25%的 APS 患者中检测到。此外，在与血栓形成相关的疾病（包括子痫前期）、其他自身免疫性疾病和癌症中也检测到了抗 ANXA2 Ab。